PBH vs. RARE, AXSM, BHVN, BHC, XENE, FOLD, IDYA, CBAY, ARWR, and HCM
Should you be buying Prestige Consumer Healthcare stock or one of its competitors? The main competitors of Prestige Consumer Healthcare include Ultragenyx Pharmaceutical (RARE), Axsome Therapeutics (AXSM), Biohaven (BHVN), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Arrowhead Pharmaceuticals (ARWR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry.
Prestige Consumer Healthcare (NYSE:PBH) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Prestige Consumer Healthcare has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 11 mentions for Ultragenyx Pharmaceutical and 8 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.01 beat Ultragenyx Pharmaceutical's score of 0.32 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.
Prestige Consumer Healthcare has a net margin of -7.11% compared to Ultragenyx Pharmaceutical's net margin of -139.70%. Prestige Consumer Healthcare's return on equity of 14.09% beat Ultragenyx Pharmaceutical's return on equity.
Ultragenyx Pharmaceutical received 321 more outperform votes than Prestige Consumer Healthcare when rated by MarketBeat users. Likewise, 77.14% of users gave Ultragenyx Pharmaceutical an outperform vote while only 70.67% of users gave Prestige Consumer Healthcare an outperform vote.
Prestige Consumer Healthcare currently has a consensus target price of $110.00, suggesting a potential upside of 56.96%. Ultragenyx Pharmaceutical has a consensus target price of $88.08, suggesting a potential upside of 100.86%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Prestige Consumer Healthcare.
100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 1.6% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Ultragenyx Pharmaceutical beats Prestige Consumer Healthcare on 10 of the 18 factors compared between the two stocks.
Get Prestige Consumer Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prestige Consumer Healthcare Competitors List
Related Companies and Tools
